Head to Head Stocks: Cimarex Energy Co (NYSE:XEC), GlaxoSmithKline PLC (NYSE:GSK)

Cimarex Energy Co (NYSE:XEC)

Cimarex Energy Co (NYSE:XEC) closed at $90.61 on the last trading session with an decrease of -2.77%, whereas, it previously closed at $93.19. The company has a market capitalization of $8.65 Billion. The company traded shares of 2.45 Million on the trading day while its three month average volume stands at 1.44 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Cimarex Energy Co (NYSE:XEC) produced diluted EPS of 5.58. The EPS estimate for next year as estimated by analysts is at 8.33 while EPS for next quarter is estimated at 1.54. Earnings per Share growth for this year is reported at 203.7, while the analysts estimated the EPS growth for next year at 8.33% and Earnings growth for next 5 years stands at 54.02% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 2.2%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Cimarex Energy Co (NYSE:XEC) is at 16.23 while the forward p/e is at 10.88. The P/S or Price to Sales ratio of Cimarex Energy Co (NYSE:XEC) stands at 4.05 and Price to Book or P/B for the most recent quarter stands at 2.94. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Cimarex Energy Co (NYSE:XEC) are reported at 1.3 and 1.3 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Cimarex Energy Co (NYSE:XEC) stands at 11.3, 22 and 11.7 respectively

The trailing twelve month Revenue of Cimarex Energy Co (NYSE:XEC) is reported at 2.14 Billion with income of 523.1 Million. The outstanding shares of Cimarex Energy Co (NYSE:XEC) are 95.51 Million. The institutional Ownership of the shares of 0 stands at 0.80%, this figure is decreased -1.18 in the last six months. The insider ownership for the shares of Cimarex Energy Co (NYSE:XEC) is ticked at 0.3%, the figure is plummeted -0.61% in the last six months.

Some other important financial aspects to be discussed here for Cimarex Energy Co (NYSE:XEC) is the Mean Target Price estimated by the analysts which stands at 122.84. The 52 week high of Cimarex Energy Co (NYSE:XEC) is placed at 130.16 and 52 week low is standing at 77.63.

Performance wise the shares of Cimarex Energy Co (NYSE:XEC) rose up 12.04% for the week, it also fell -6.66% for the monthly performance, while for the quarter it went down 0.69%. The shares decrease -8.05% for the half year and plummeted for the Year-To-Date performance. The shares of Cimarex Energy Co (NYSE:XEC) shrinked -27.71% for the yearly performance.

GlaxoSmithKline PLC (NYSE:GSK)

GlaxoSmithKline PLC (NYSE:GSK) closed at $41.24 on the last trading session with an increase of 1.05%, whereas, it previously closed at $40.81. The company has a market capitalization of $103.61 Billion. The company traded shares of 2.45 Million on the trading day while its three month average volume stands at 2.46 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of GlaxoSmithKline PLC (NYSE:GSK) produced diluted EPS of 1.44. The EPS estimate for next year as estimated by analysts is at 2.96 while EPS for next quarter is estimated at 0.67. Earnings per Share growth for this year is reported at 184, while the analysts estimated the EPS growth for next year at 2.96% and Earnings growth for next 5 years stands at 8.8% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -10.1%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of GlaxoSmithKline PLC (NYSE:GSK) is at 28.6 while the forward p/e is at 13.92. The P/S or Price to Sales ratio of GlaxoSmithKline PLC (NYSE:GSK) stands at 2.65 and Price to Book or P/B for the most recent quarter stands at 17.4. The Price to Free Cash Flow ratio or P/FCF is reported at 56.49. The quick ratio and the current ratio of GlaxoSmithKline PLC (NYSE:GSK) are reported at 0.6 and 0.9 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for GlaxoSmithKline PLC (NYSE:GSK) stands at 3.3, 92.9 and 22.9 respectively

The trailing twelve month Revenue of GlaxoSmithKline PLC (NYSE:GSK) is reported at 39.05 Billion with income of 3.56 Billion. The outstanding shares of GlaxoSmithKline PLC (NYSE:GSK) are 2.51 Billion. The institutional Ownership of the shares of 11.4 stands at 0.80%, this figure is decreased -0.19 in the last six months. The insider ownership for the shares of GlaxoSmithKline PLC (NYSE:GSK) is ticked at 0.2%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for GlaxoSmithKline PLC (NYSE:GSK) is the Mean Target Price estimated by the analysts which stands at 44.3. The 52 week high of GlaxoSmithKline PLC (NYSE:GSK) is placed at 42.36 and 52 week low is standing at 34.52.

Performance wise the shares of GlaxoSmithKline PLC (NYSE:GSK) rose up 3.91% for the week, it also rise 5.12% for the monthly performance, while for the quarter it went down 2.71%. The shares increase 3.02% for the half year and flew up for the Year-To-Date performance. The shares of GlaxoSmithKline PLC (NYSE:GSK) grew 13.05% for the yearly performance.